Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583–599) of human immunodeficiency virus type 1

Borrebaeck, 1988, Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes, 85, 3995 Boyer, 1991, Characterization and large production of human monoclonal antibodies against the HIV-1 envelope, Clin. exp. Immunol., 83, 452, 10.1111/j.1365-2249.1991.tb05660.x Celada, 1990, Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding, J. exp. Med., 172, 1143, 10.1084/jem.172.4.1143 Cheingsong-Popov, 1990, Antibodies to a putative HIV gp41 immunosuppressive peptide, pHIVIS (583–599), do not correlate significantly with outcome in HIV infection, AIDS, 4, 251, 10.1097/00002030-199003000-00012 Cianciolo, 1988, Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation, Immunol. Letters, 19, 7, 10.1016/0165-2478(88)90112-5 Cordell, 1991, Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro, Virology, 185, 72, 10.1016/0042-6822(91)90755-Z Dalgleish, 1988, Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide, Virology, 165, 209, 10.1016/0042-6822(88)90674-5 Döpel, 1989, Fine mapping of an immunodominant region of the transmembrane protein of the human immunodeficiency virus (HIV-1), J. virol. Methods, 25, 167, 10.1016/0166-0934(89)90030-X Durda, 1990, HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide, AIDS Res. Hum. Retrovirus, 6, 1115, 10.1089/aid.1990.6.1115 Hammond, 1991, Characterization of a conserved T-cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells, J. Immunol., 146, 1470 Ho, 1987, Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins, J. Virol., 61, 2024, 10.1128/JVI.61.6.2024-2028.1987 Klasse, 1988, Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects, 85, 5225 Lange, 1989, Antibodies to an HIV-1 synthetic peptide with partial homology to MULV p15E do not protect against AIDS, AIDS, 3, 402, 10.1097/00002030-198906000-00013 Matsushita, 1988, Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope, J. Virol., 62, 2107, 10.1128/JVI.62.6.2107-2114.1988 Matthews, 1986, Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein, 83, 9709 Modrow, 1987, Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions, J. Virol., 61, 570, 10.1128/JVI.61.2.570-578.1987 Nara, 1987, Simple, rapid, quantitative micro-syncytium forming assay for the detection of neutralizing antibody against infectious HTLV-III/LAV, AIDS Res. Hum. Retrovirus, 3, 283, 10.1089/aid.1987.3.283 Qureshi, 1990, Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides, AIDS, 4, 553, 10.1097/00002030-199006000-00009 Reitz, 1988, Generation of a neutralizing-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene, Cell, 54, 57, 10.1016/0092-8674(88)90179-1 Robert-Guroff, 1985, HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex, Nature (Lond.), 316, 72, 10.1038/316072a0 Robertson, 1988, A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity, J. virol. Methods, 20, 195, 10.1016/0166-0934(88)90123-1 Robinson, 1989, Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release, J. AIDS, 2, 33 Robinson, 1990, Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro, J. Virol., 64, 5301, 10.1128/JVI.64.11.5301-5305.1990 Ruegg, 1989, Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1, J. Virol., 63, 3257, 10.1128/JVI.63.8.3257-3260.1989 Scott, 1990, Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type III MN strain, 87, 8597 Shafferman, 1991, Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences, 88, 7126 Skinner, 1988, Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein, AIDS Res. Hum. Retroviruses, 4, 187, 10.1089/aid.1988.4.187 Skinner, 1988, Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4, J. Virol., 62, 4195, 10.1128/JVI.62.11.4195-4200.1988 Trabaud, 1989, Human monoclonal antibodies with a protective activity against tetanus toxin, Acta path. microbiol. immunol. Scand., 97, 671, 10.1111/j.1699-0463.1989.tb00461.x Weiss, 1985, Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients, Nature (Lond.), 316, 69, 10.1038/316069a0 Wilson, 1990, The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope, J. Virol., 64, 3240, 10.1128/JVI.64.7.3240-3248.1990